Drug Profile
Pexmetinib - Pfizer
Alternative Names: ARRY 614; Pexmetinib hydrochlorideLatest Information Update: 23 Oct 2023
Price :
$50
*
At a glance
- Originator Array BioPharma
- Class Anti-inflammatories; Antineoplastics; Indazoles; Pyrazoles; Small molecules; Urea compounds
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors; TIE 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation; Malignant melanoma; Myelodysplastic syndromes; Renal cell carcinoma; Solid tumours
Most Recent Events
- 20 Oct 2023 Discontinued - Phase-I for Myelodysplastic syndromes in USA (PO) prior to October 2023 (Pfizer pipeline, October 2023)
- 20 Oct 2023 Discontinued - Phase-I/II for Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) prior to October 2023 (Pfizer pipeline, October 2023)
- 20 Oct 2023 Discontinued - Phase-I/II for Renal cell carcinoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) prior to October 2023 (Pfizer pipeline, October 2023)